Trial intelligence / Profile preview

Genomic predictors of GLP-1–related therapy effects in severe obesity

jRCT1031230422Recruiting

Sponsor: Clinical Research Initiation Fund
Start: Oct 2023
Modality: Recombinant Proteins and Enzymes, Peptides
Countries: 1

Overview

Open-label trial of tirzepatide and semaglutide in obesity, prediabetes, type 2 diabetes mellitus (T2DM) and 5 more (2 arms), sponsored by Clinical Research Initiation Fund. Primary endpoint: Primary: Association between 12-month HbA1c change and genotype. Started Oct 2023; status: recruiting.

Drugs

tirzepatidesemaglutide

Conditions

obesityprediabetestype 2 diabetes mellitus (T2DM)dyslipidemiametabolic dysfunction-associated steatotic liver disease (MASLD)

Beyond the preview

Go deeper on jRCT1031230422.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT1031230422.